A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

INTRODUCTION: Metastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV) represent a novel approach to immunotherapy for patients with MUM. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Katherine E. R., Peng, Kah-Whye, Pulido, Jose S., Weisbrod, Adam J., Strand, Carrie A., Allred, Jacob B., Newsom, Alysha N., Zhang, Lianwen, Packiriswamy, Nandakumar, Kottke, Timothy, Tonne, Jason M., Moore, Madelyn, Montane, Heather N., Kottschade, Lisa A., McWilliams, Robert R., Dudek, Arkadiusz Z., Yan, Yiyi, Dimou, Anastasios, Markovic, Svetomir N., Federspiel, Mark J., Vile, Richard G., Dronca, Roxana S., Block, Matthew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644866/
https://www.ncbi.nlm.nih.gov/pubmed/38022659
http://dx.doi.org/10.3389/fimmu.2023.1279387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644866/
https://www.ncbi.nlm.nih.gov/pubmed/38022659
http://dx.doi.org/10.3389/fimmu.2023.1279387

Ejemplares similares